Meet with Inoviv at the
Alzheimer’s Association International Conference 2024 (AAIC24)
Conference Details
Date: July 28 – August 1, 2024
Meet with us at Booth #714
Location: Philadelphia, USA
About Inoviv
Join us at AAIC to discover how Inoviv is advancing Alzheimer’s research with our cutting-edge technology, enabling highly sensitive and precise biomarker detection. Our innovative solutions are designed to accelerate the development of therapeutics and enhance clinical trials. Connect with us to explore how we can support your research and contribute to breakthroughs in Alzheimer’s disease.
Meet us at Booth #714 to discuss the following:
AAIC 2024
The Alzheimer’s Association International Conference (AAIC) will bring together more than 7,000 leaders from the global medical and scientific dementia researcher community. They are clinicians, scientists, researchers, lab managers and care providers who have regular contact with thousands of patients and they come to learn about the latest research, products and solutions available in the treatment of Alzheimer’s and related dementias.
Alzheimer’s is tricky to understand
There is a lack of disease-specific biomarkers for early diagnosis and treatment efficacy monitoring
Most well-defined biomarkers exist in minute amounts, posing significant detection challenges with conventional assays
There is a strong need for non-invasive treatment efficacy monitoring and patient stratification methods due to long clinical trials
Proteomics and their utility as robust molecular fingerprints
Researchers can efficiently identify dysregulated Alzheimer’s markers, providing insights into disease mechanisms and treatment targets
Mass spectrometry can identify early-onset Alzheimer’s markers, aiding disease staging and therapy monitoring non-invasively, and is well-positioned for exceptional specificity, sensitivity, and accuracy for CSF, plasma, and more
Robust LC-MS solutions for Alzheimer’s therapeutic development
Inoviv’s end-to-end discovery to targeted proteomics helps drug developers understand novel dysregulated Alzheimer’s markers, and translate those findings into a fully validated targeted assay for treatment monitoring and patient stratification
Our proprietary analytical algorithms, workflows, and internal standards provide the highest possible reproducibility and robustness across thousands of samples with a linear dynamic range over six orders of magnitude
